{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-119064","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.745781+00:00","generated_at":"2026-05-30T00:15:47.393439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Traws Pharma Q3 net loss $8.5M; cash $5.4M; Phase 2 starts for COVID and flu drugs in 2025","bullets":["Net loss of $8.5M ($8.81 per share) vs $4.7M loss in Q3 2023; R&D expense $5.1M, G&A $3.5M.","Cash and short-term investments $5.4M as of Sept 30, down from $20.8M at Dec 31, 2023.","Ratutrelvir (COVID) Phase 1 data supports once-daily dosing without ritonavir; Phase 2 targeted in 2025.","Tivoxavir marboxil (flu) Phase 1 data supports single-dose treatment; Phase 2 targeted in 2025.","Luba Greenwood appointed to board of directors; shares outstanding 3,025,554 after 25:1 reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-119064","json":"https://secwatch.observer/filing/0001104659-24-119064.json","markdown":"https://secwatch.observer/filing/0001104659-24-119064.md","text":"https://secwatch.observer/filing/0001104659-24-119064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924119064/0001104659-24-119064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924119064/tm2428509d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:15:47.393439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}